(SRDX) SurModics - Ratings and Ratios
Coatings,Proteins,Substrates,Antigens,Balloons
SRDX EPS (Earnings per Share)
SRDX Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 31.3% |
| Value at Risk 5%th | 42.3% |
| Relative Tail Risk | -17.95% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.32 |
| Alpha | -1.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.517 |
| Beta | 0.492 |
| Beta Downside | 0.482 |
| Drawdowns 3y | |
|---|---|
| Max DD | 55.53% |
| Mean DD | 19.54% |
| Median DD | 17.93% |
Description: SRDX SurModics October 25, 2025
Surmodics, Inc. (NASDAQ: SRDX) supplies performance-coating technologies for intravascular medical devices and chemical/biological components for in-vitro diagnostic (IVD) immunoassays and microarrays, serving customers in the United States and abroad.
The company operates through two distinct segments. The **Medical Device** segment delivers surface-modification and drug-delivery coatings that improve access, deliverability, and controlled release for neurovascular, peripheral, coronary, and structural-heart devices, and it also manufactures vascular-intervention products such as drug-coated balloons, mechanical thrombectomy tools, and radial-access balloon catheters. The **IVD** segment produces protein stabilizers, substrates, surface coatings, and antigens used in immunoassay, molecular testing, and biomedical-research applications.
Key recent metrics (Q2 2024): revenue of $112 million, representing a 14 % year-over-year increase driven largely by a 22 % rise in the Medical Device segment; gross margin improved to 62 % from 58 % a year earlier, reflecting higher mix of coating contracts; R&D spend held at ~12 % of revenue, supporting pipeline expansion in drug-eluting balloon technology. The broader market is buoyed by an aging U.S. population and a shift toward minimally invasive procedures, which together underpin a projected 7 % CAGR for the intravascular-device coating market through 2029. In the IVD space, growth is accelerated by the adoption of personalized-medicine panels, with the global IVD reagents market expected to expand at ~6 % CAGR.
For a deeper quantitative assessment, you may find ValueRay’s detailed valuation models for SRDX useful.
SRDX Stock Overview
| Market Cap in USD | 592m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1998-03-04 |
| Return 12m vs S&P 500 | -4.69% |
| Analyst Rating | 3.0 of 5 |
SRDX Dividends
Currently no dividends paidSRDX Growth Ratios
| CAGR 3y | 6.76% |
| CAGR/Max DD Calmar Ratio | 0.12 |
| CAGR/Mean DD Pain Ratio | 0.35 |
| Current Volume | 450.8k |
| Average Volume | 115.7k |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-17.6m TTM) > 0 and > 6% of Revenue (6% = 7.25m TTM) |
| FCFTA -0.02 (>2.0%) and ΔFCFTA 1.21pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 46.82% (prev 49.79%; Δ -2.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.01 (>3.0%) and CFO -1.88m > Net Income -17.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.91 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (14.3m) change vs 12m ago 0.78% (target <= -2.0% for YES) |
| Gross Margin 73.09% (prev 57.38%; Δ 15.71pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 69.58% (prev 68.10%; Δ 1.48pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.61 (EBITDA TTM -8.23m / Interest Expense TTM 3.49m) >= 6 (WARN >= 3) |
Altman Z'' 3.88
| (A) 0.33 = (Total Current Assets 76.0m - Total Current Liabilities 19.4m) / Total Assets 169.8m |
| (B) 0.36 = Retained Earnings (Balance) 61.5m / Total Assets 169.8m |
| (C) -0.09 = EBIT TTM -16.1m / Avg Total Assets 173.6m |
| (D) 1.08 = Book Value of Equity 63.4m / Total Liabilities 58.5m |
| Total Rating: 3.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.45
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -0.60% = -0.30 |
| 3. FCF Margin -2.94% = -1.10 |
| 4. Debt/Equity 0.29 = 2.46 |
| 5. Debt/Ebitda 3.19 = -2.02 |
| 6. ROIC - WACC (= -17.66)% = -12.50 |
| 7. RoE -15.59% = -2.50 |
| 8. Rev. Trend 7.69% = 0.58 |
| 9. EPS Trend -3.48% = -0.17 |
What is the price of SRDX shares?
Over the past week, the price has changed by +55.32%, over one month by +50.82%, over three months by +10.55% and over the past year by +9.24%.
Is SurModics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SRDX is around 36.13 USD . This means that SRDX is currently overvalued and has a potential downside of -13.17%.
Is SRDX a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SRDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43 | 3.3% |
| Analysts Target Price | 43 | 3.3% |
| ValueRay Target Price | 39.9 | -4% |
SRDX Fundamental Data Overview November 15, 2025
P/E Forward = 208.3333
P/S = 4.9012
P/B = 5.3159
P/EG = 3.8952
Beta = 1.39
Revenue TTM = 120.8m USD
EBIT TTM = -16.1m USD
EBITDA TTM = -8.23m USD
Long Term Debt = 29.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.02m USD (from shortTermDebt, last quarter)
Debt = 32.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.3m USD (from netDebt column, last quarter)
Enterprise Value = 591.9m USD (592.1m + Debt 32.6m - CCE 32.7m)
Interest Coverage Ratio = -4.61 (Ebit TTM -16.1m / Interest Expense TTM 3.49m)
FCF Yield = -0.60% (FCF TTM -3.55m / Enterprise Value 591.9m)
FCF Margin = -2.94% (FCF TTM -3.55m / Revenue TTM 120.8m)
Net Margin = -14.59% (Net Income TTM -17.6m / Revenue TTM 120.8m)
Gross Margin = 73.09% ((Revenue TTM 120.8m - Cost of Revenue TTM 32.5m) / Revenue TTM)
Gross Margin QoQ = 70.99% (prev 72.12%)
Tobins Q-Ratio = 3.49 (Enterprise Value 591.9m / Total Assets 169.8m)
Interest Expense / Debt = 2.65% (Interest Expense 865.0k / Debt 32.6m)
Taxrate = 10.31% (-611.0k / -5.93m)
NOPAT = -14.4m (EBIT -16.1m * (1 - 10.31%)) [loss with tax shield]
Current Ratio = 3.91 (Total Current Assets 76.0m / Total Current Liabilities 19.4m)
Debt / Equity = 0.29 (Debt 32.6m / totalStockholderEquity, last quarter 111.3m)
Debt / EBITDA = 3.19 (negative EBITDA) (Net Debt -26.3m / EBITDA -8.23m)
Debt / FCF = 7.41 (negative FCF - burning cash) (Net Debt -26.3m / FCF TTM -3.55m)
Total Stockholder Equity = 113.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.38% (Net Income -17.6m / Total Assets 169.8m)
RoE = -15.59% (Net Income TTM -17.6m / Total Stockholder Equity 113.1m)
RoCE = -11.27% (EBIT -16.1m / Capital Employed (Equity 113.1m + L.T.Debt 29.7m))
RoIC = -10.11% (negative operating profit) (NOPAT -14.4m / Invested Capital 142.7m)
WACC = 7.55% (E(592.1m)/V(624.6m) * Re(7.83%) + D(32.6m)/V(624.6m) * Rd(2.65%) * (1-Tc(0.10)))
Discount Rate = 7.83% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
Fair Price DCF = unknown (Cash Flow -3.55m)
EPS Correlation: -3.48 | EPS CAGR: -17.60% | SUE: 0.29 | # QB: 0
Revenue Correlation: 7.69 | Revenue CAGR: 4.80% | SUE: 0.27 | # QB: 0
Additional Sources for SRDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle